A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)

NCT00136409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis
Myeloid Metaplasia
Agnogenic Myeloid Metaplasia
Chronic Myelomonocytic Leukemia

Interventions

DRUG: Imatinib mesylate

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]